200 Penobscot DrIve
Redwood City, CA 94063
About Codexis, Inc.
Since 2002, Codexis' works every day to unlock the power of proteins®!
Our vision for the future
We discover and develop more effective therapeutics, enable healthier choices, innovate sustainable processes and products, and reduce waste – all to create a brighter future. This unified vision is what drives Codexis to continually set high standards and raise expectations of what is possible and its impact on the world and communities around us.
Creating a sustainable world
Enabling sustainable processes and products is our priority towards reducing waste, pollution, and consumption. Enzymes, nature’s biocatalysts for millions of years, are significantly more safe for the environment than are chemicals. We engineer high-performance enzymes to enable industrial bioprocesses that address productivity needs without sacrificing the health of our planet.
Commitment to human health
We are committed to effective biological therapeutics and accurate health monitoring tools. Annually, Codexis participates in global Rare Disease Day and also hosts its own event, welcoming guests and patient support groups with onsite activities. Whether it is for novel pharmaceuticals, protein therapies, gene therapies, biosensors, or upstream research and development, our work – evolved enzymes – makes an impact on someone’s life daily. This is why we at Codexis continue to work harder and smarter; we believe every breath and every heartbeat matters.
Commitment to community
As a socially responsible company, Codexis strives to play a positive role by fostering a culture that promotes employee volunteering to support the communities where we operate. We participate in multiple initiatives throughout the year supporting local charitable organizations, Family Giving Tree, and Second Harvest Food Bank. To promote youth education, Codexis sponsors Future Protein Engineers, an online program encouraging innovation and creativity while having fun learning about science.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
17 articles with Codexis, Inc.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
Codexis, Inc. announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four.
Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences.
Codexis, Inc., a leading enzyme engineering company, announced that management will participate in three upcoming virtual investment conferences.
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the first quarter ended March 31, 2021 and provided a business update.
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2021 on Thursday, May 6, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
Strong Product Revenue Momentum in Second Half of 2020 Drives Company’s Seventh Consecutive Year of YOY Revenue Growth
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences.
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
Codexis, Inc., a leading enzyme engineering company, announced it will be expanding its operations into a new 36,000 square foot facility in San Carlos, CA under a ten year lease.
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.
Codexis, Inc., a leading protein engineering company and developer of high-performance enzymes, and Tate & Lyle, a leading global provider of food ingredients and solutions, have extended and deepened their relationship to enhance the production of two of Tate & Lyle’s newest sweeteners: DOLCIA PRIMA® Allulose and TASTEVA® M Stevia Sweetener.
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that John Nicols, the Company’s President and Chief Executive officer, will participate in a fireside chat presentation at the H.C. Wainwright BioConnect 2021 Conference, being held virtually January 11-14, 2021. A replay of the pre-recorded fireside chat will be available beginning Monday, January 11, at 6:00 a.m. ET and will be archived on the Investor
Codexis, Inc., a leading protein engineering company, announced the pricing of an underwritten public offering of 4,285,715 shares of its common stock at a public offering price of $17.50 per share.
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock.
Codexis, Inc., a leading protein engineering company, announces that management will participate at three upcoming virtual investment conferences
Higher sequential sales expected again in the fourth quarter, showing growing momentum as we close 2020